期刊
CURRENT OPINION IN NEUROLOGY
卷 30, 期 3, 页码 361-369出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/WCO.0000000000000451
关键词
glioblastoma; immune checkpoint; immunosuppression; programmed death-1; vaccine
资金
- Celldex Therapeutics
- Incyte
- Midatech
- Acerta
- Agios
- Angiochem
- AstraZeneca
- Ely Lilly
- Genentech/Roceh
- Karyopharm
- Merck
- Novartis
- Oncoceutics
- Sanofi-Aventis
- Vascular Biogenics
- Astellas
- BMS
- Celldex
Purpose of review Immunotherapy has emerged as a cornerstone of modern oncology with regulatory approvals for a variety of immunotherapeutics being achieved for a spectrum of cancer indications. Nonetheless the role of these approaches for patients with glioblastoma (GBM), the most common and deadliest primary malignant brain neoplasm, remains unknown. In this review, we summarize the current status of clinical development for the major types of immunotherapeutics, including vaccines, cell-based therapies, and immune checkpoint modulators for GBM. We also highlight potential challenges confronting the development of these agents. Recent findings Growing preclinical and clinical data is emerging regarding the potential of immunotherapy strategies for GBM. In parallel, growing data demonstrating that historical dogma classifying the brain as immunoprivileged is inaccurate but that many tumors, including GBM evoke myriad mechanisms to suppress antitumor immune responses. Summary Ongoing initial trials will provide preliminary data on the role of immunotherapy for GBM patients. Subsequent clinical development steps will likely require rationally designed combinatorial regimens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据